RxDoctor Payments Data

Karen Cheek

Nurse Practitioner · Manchester, KYNPI 1316052442

Payments from drug & device makers

$1,072in general payments, 2019–2025

Across 55 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$269
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$232
  • AstraZeneca$103
  • Lilly USA, LLC$93
  • Otsuka America Pharmaceutical, Inc.$83
  • Vanda Pharmaceuticals Inc.$67
  • plus $226 from 11 others

What the payments were for

  • Food & beverage$1,00293%
  • Education$707%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,072 in reported general payments places this provider in the 70th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,052
Medicare patients
12
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$103,318
EliquisApixaban90$72,405
LinzessLinaclotide107$72,043
MounjaroTirzepatide57$60,168
JanuviaSitagliptin Phosphate62$49,221
JardianceEmpagliflozin61$48,310
FarxigaDapagliflozin Propanediol48$42,380
EntrestoSacubitril/Valsartan40$42,210
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$22,714
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,005
Humalog Kwikpen U-200Insulin Lispro17$16,158
Nurtec OdtRimegepant Sulfate15$15,285
Albuterol Sulfate HfaAlbuterol Sulfate297$9,633
Tresiba Flextouch U-100Insulin Degludec18$9,010
Tresiba Flextouch U-200Insulin Degludec11$8,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$17$87,689105 claims
AbbVieLinzess, Synthroid$269$73,244125 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$103$69,25688 claims
Lilly USA, LLCMounjaro$93$60,16857 claims
MerckJanuvia$35$49,22162 claims
Hikma Pharmaceuticals USAEpinephrine$21$4,46922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Manchester

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →